Stay updated with breaking news from Therapy Alone. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan reduced the risk of disease progression or death by 37%, providing a 2-month median PFS benefit, and was well tolerated in post-endocrine...
First Phase III results in breast cancer for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan Plans for global regulatory submissions underway ...
Decision based on CAPItello-291 Phase III trial results which showed the combination reduced the risk of disease progression or death by 40% vs. FASLODEX alone Potential first-in-class AKT... | June 12, 2023
Camizestrant significantly delayed disease progression in advanced ER-positive breast cancer, adding at least 3.5 months benefit versus FASLODEX® (fulvestrant) SERENA-2 Phase II trial results presented at SABCS 2022 show potential of camizestrant as next-generation SERD in endocrine therapy WILMINGTON...
Capivasertib plus FASLODEX® (fulvestrant) reduced the risk of disease progression or death by 40% versus FASLODEX in advanced HR-positive breast cancer CAPItello-291 Phase III trial results presented at SABCS 2022 show potential of capivasertib as first-in-class AKT inhibitor WILMINGTON, Del., Decembe...